Inhaler Corticosteroid Device Market Growth and Restrain Factors Analysis Report

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Inhaler Corticosteroid Device Market- (By Steroid Types (Beclomethasone Dipropionate, Budesonide, Fluticasone Inhaler Powder, & Mometasone), By Application (Asthma, COPD (Chronic Obstructive Pulmonary Disease) and Others) By End-user (Hospitals and Clinics, Academic and Research Institutes and Respiratory Care Center)) Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Inhaler Corticosteroid Device Market is valued at US$ 616.09 Mn in 2023, and it is expected to reach US$ 886.4 Mn by 2031, with a CAGR of 4.6% during the forecast period of 2024-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2441

Inhaled corticosteroids (ICS) continue to play a critical role in the long-term management of respiratory diseases, particularly asthma. The increasing prevalence of asthma, driven in part by rising environmental pollution, has spurred the development of advanced ICS delivery devices by pharmaceutical and medical device manufacturers, thereby contributing to the growth of the inhaled corticosteroid device market.

The market includes a variety of devices designed to administer corticosteroids directly to the lungs, ensuring targeted and effective therapy. Key delivery systems, including metered-dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers, are essential components of maintenance treatment regimens for patients with chronic respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD).

List of Prominent Players in the Inhaler Corticosteroid Device Market:
• Pfizer Inc.
• GlaxoSmithKline plc
• Novartis AG
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Boehringer Ingelheim International GmbH.
• AstraZeneca
• F. Hoffmann-La Roche Ltd.
• Bristol-Myers Squibb Company
• Amgen Inc.
• Aurobindo Pharma
• Eli Lilly and Company
• Cipla Inc.
• Sumitomo Corporation

Market Dynamics:
Drivers-
The rising prevalence of asthma is a primary factor driving the growth of the inhaled corticosteroid (ICS) device market. Asthma, a chronic respiratory disorder affecting both the upper and lower airways, causes inflammation and airway obstruction. The condition is particularly common among pediatric and geriatric populations, who benefit from user-friendly treatment options. ICS devices have become a preferred solution for managing asthma symptoms due to their targeted delivery and ease of use, enhancing both treatment adherence and therapeutic effectiveness.

Enquiry Before Buying:
https://www.insightaceanalytic.com/enquiry-before-buying/2441

Challenges:
Despite strong growth potential, the market faces several challenges. Patent expirations and the resulting increase in generic alternatives are likely to reduce market share for branded ICS products. In developing regions, limited healthcare infrastructure and the high cost of inhaled corticosteroids remain significant barriers to adoption. Additionally, potential side effects-such as oral thrush, cough, hoarseness, and sore throat-can discourage patient use and impact overall market uptake. Cost-sensitive healthcare practices further influence purchasing decisions among providers and payers, shaping market dynamics.

Regional Trends:
North America maintains a dominant position in the inhaled corticosteroid device market, driven by advanced healthcare infrastructure, a high prevalence of respiratory diseases, and a strong emphasis on technological innovation. The region's large patient population requiring long-term respiratory therapy continues to support market demand. Furthermore, sustained investments in research and development, strategic collaborations between pharmaceutical companies and academic institutions, and favorable reimbursement policies reinforce North America's leadership and contribute to ongoing market growth.

Recent Developments:
• In September 2020, GlaxoSmithKline plc and Innoviva, Inc. announced the U.S. Food and Drug Administration (FDA) approval for a new indication of Trelegy Ellipta. It is also used to treat patients suffering from chronic obstructive pulmonary disease (COPD).
• BreatheSuite is a 2018 startup firm based in St.Johns, Canada. It has developed an integrated inhaler device for medication adherence to manage COPD and asthma.
• CareTRx is a mobile app and sensor offered by Gecko Health for the management of asthma. The device is added to pre-existing inhalers. It aims at assisting patients to better manage their asthma by tracking medication use.

Unlock Your GTM Strategy:
https://www.insightaceanalytic.com/customisation/2441

Segmentation of Global Inhaler Corticosteroid Device Market-
Global Inhaler Corticosteroid Device Market- By Steroid Types
• Beclomethasone Dipropionate
• Budesonide
• Fluticasone Inhaler Powder
• Mometasone
Global Inhaler Corticosteroid Device Market- By Application
• Asthma
• COPD (Chronic Obstructive Pulmonary Disease)
• Others
Global Inhaler Corticosteroid Device Market- By End-User
• Hospitals and Clinics
• Academic and Research Institutes
• Respiratory Care Center
Global Inhaler Corticosteroid Device Market- By Region
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Get More Information :
https://www.insightaceanalytic.com/report/inhaler-corticosteroid-device-market/2441

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.https://www.insightaceanalytic.com/images_data/148861653.

Contact Us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Official Site Visit: www.insightaceanalytic.com
Tel.: +1 607 400-7072
Email: info@insightaceanalytic.com
Follow US On :
LinkedIn @ https://www.linkedin.com/company/insightace-analytic-pvt-ltd/
Twitter @ https://x.com/MInsightace
YouTube @ https://www.youtube.com/@InsightAceAnalytic
Instagram @https://www.instagram.com/insight_ace_analytic/

This release was published on openPR.